Royce & Associates LP Buys 34,540 Shares of Bioventus Inc. (NYSE:BVS)

Royce & Associates LP increased its stake in Bioventus Inc. (NYSE:BVS) by 5.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 732,236 shares of the company’s stock after purchasing an additional 34,540 shares during the quarter. Royce & Associates LP’s holdings in Bioventus were worth $7,688,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Plato Investment Management Ltd bought a new position in shares of Bioventus during the fourth quarter worth about $38,000. Virtus Fund Advisers LLC acquired a new position in Bioventus during the 3rd quarter worth approximately $42,000. Quest Partners LLC bought a new position in shares of Bioventus during the 3rd quarter worth approximately $51,000. Quarry LP acquired a new stake in shares of Bioventus in the third quarter valued at approximately $59,000. Finally, Arizona State Retirement System bought a new stake in shares of Bioventus in the fourth quarter worth $109,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Insider Buying and Selling

In other Bioventus news, CFO Mark Leonard Singleton sold 6,498 shares of Bioventus stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Katrina J. Church sold 2,535 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $26,693.55. Following the completion of the transaction, the senior vice president now directly owns 47,264 shares in the company, valued at $497,689.92. The trade was a 5.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,950 shares of company stock worth $522,437. Company insiders own 32.90% of the company’s stock.

Bioventus Stock Performance

Shares of BVS opened at $9.56 on Wednesday. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a 50-day moving average of $10.08 and a 200-day moving average of $11.01. The company has a market cap of $775.84 million, a PE ratio of -15.67 and a beta of 0.86. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Analysts Set New Price Targets

A number of research analysts recently weighed in on BVS shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research report on Monday. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and raised their price target for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.